Exploratory Study of Pagoclone in Men With Premature Ejaculation.

A Four-arm, Randomized, Double-blind, Parallel, Placebo-controlled Exploratory Study of Pagoclone 0.15mg, 0.30mg, and 0.60mg in Men With Primary Premature Ejaculation.

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00370981

Enrollment

100

Registered

2006-09-01

Start date

2006-07-31

Completion date

2006-10-31

Last updated

2013-12-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Premature Ejaculation

Keywords

investigational drug, ejaculation

Brief summary

The purpose of this study is to evaluate pagoclone in the treatment of premature ejaculation.

Detailed description

The primary objective of this study is to evaluate the effect of 3 dose levels of pagoclone (0.15 mg, 0.30 mg, and 0.60 mg) versus placebo on intravaginal ejaculation latency time (IELT) male patients with primary premature ejaculation.

Interventions

DRUGpagoclone

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

MALE

Age

18 Years to 55 Years

Healthy volunteers

Inclusion criteria

* A male regularly experiencing premature ejaculation * 18 to 55 yrs old * In a Stable relationship with one woman for at least 6 months

Design outcomes

Primary

Measure	Time frame
Intravaginal ejaculation latency time (IELT)	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026